NFKB1 and esophageal squamous cell carcinoma: Future research could explore targeted therapeutic strategies, such as JAK-STAT or NF-κB pathway inhibitors, in combination with neoantigen prediction, to develop combined immunotherapeutic approaches, further optimizing treatment outcomes for ESCC patients.